CH
TARA icon

CVI Holdings’s Protara Therapeutics TARA Stock Holding History

CVI Holdings’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$630K Buy
+302,746
New +$885K 0.54% 28
2020
Q4 		– Sell
-168,836
Closed -$2.84M – 190
2020
Q3 		$2.84M Buy
+168,836
New +$3.92M 1.15% 24

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

CVI Holdings's TARA Position: Q2 2024 in Review

CVI Holdings opened a new position in Protara Therapeutics (TARA) in Q2 2024: 302,746 shares worth $630K. The stake represents 0.54% of the portfolio and ranks #28 among its holdings. This is a return to the name: CVI Holdings previously reported a position in TARA as recently as Q3 2020.

CVI Holdings first reported a position in TARA in Q3 2020 and has held it in 2 quarters since. The position peaked at $2.84M in Q3 2020. 38 funds tracked by Wall St. Rank hold TARA as of Q2 2024.

  • CVI Holdings held 302,746 shares of Protara Therapeutics worth $630K as of Q2 2024.
  • Protara Therapeutics was a new CVI Holdings position in Q2 2024.
  • Protara Therapeutics made up 0.54% of CVI Holdings's portfolio in Q2 2024, its #28 holding.
  • CVI Holdings first reported a position in Protara Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • CVI Holdings's Protara Therapeutics position peaked at $2.84M in Q3 2020.
  • 38 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2024.

Based on CVI Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.